Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Zobrazit další vydání (2)

Background: Evaluating the long term benefit of therapy in multiple sclerosis (MS) is challenging. Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established. Methods: In a patie...

Podrobná bibliografie
Hlavní autoři:	Goodin, D, Traboulsee, A, Knappertz, V, Reder, A, Li, D, Langdon, D, Wolf, C, Beckmann, K, Konieczny, A, Ebers, G
Médium:	Journal article
Vydáno:	2012

Podobné jednotky

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
Autor: Goodin, D, a další
Vydáno: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Autor: Goodin, D, a další
Vydáno: (2012)

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
Autor: Goodin, D, a další
Vydáno: (2012)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
Autor: Goodin, D, a další
Vydáno: (2012)

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Autor: Ebers, G, a další
Vydáno: (2009)

Mortality in patients with multiple sclerosis.
Autor: Scalfari, A, a další
Vydáno: (2013)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Autor: Ebers, G, a další
Vydáno: (2010)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
Autor: Ebers, G, a další
Vydáno: (2011)

The final results of the interferon beta-1b 16-year long-term follow-up study
Autor: Ebers, G, a další
Vydáno: (2006)

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes
Autor: Reder, A, a další
Vydáno: (2008)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Autor: Reder, A, a další
Vydáno: (2010)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
Autor: Langdon, D, a další
Vydáno: (2007)

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
Autor: Douglas S Goodin, a další
Vydáno: (2011-01-01)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
Autor: Ebers, G, a další
Vydáno: (2005)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
Autor: Ebers, G, a další
Vydáno: (2004)

Causes of death among commercially insured multiple sclerosis patients in the United States.
Autor: Douglas S Goodin, a další
Vydáno: (2014-01-01)

Treatment of multiple sclerosis with interferon beta-1b - Reply
Autor: Sibley, W, a další
Vydáno: (1997)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
Autor: Sibley, W, a další
Vydáno: (1994)

Interferons in relapsing remitting multiple sclerosis.
Autor: Goodin, D
Vydáno: (2003)

Cause of death in MS: Longterm follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study (BMJ Open (2012) 2 (e001972))
Autor: Goodin, D, a další
Vydáno: (2013)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Autor: Petkau, A, a další
Vydáno: (2004)

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
Autor: Colin J. Ross, a další
Vydáno: (2017-05-01)

Systemic interferon alfa in multiple sclerosis.
Autor: Weinshenker, BG, a další
Vydáno: (1989)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
Autor: Ebers, G, a další
Vydáno: (1997)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Autor: Filippini, G, a další
Vydáno: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Autor: Filippini, G, a další
Vydáno: (2003)

Age and disability accumulation in multiple sclerosis.
Autor: Scalfari, A, a další
Vydáno: (2011)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
Autor: Paul I. Creeke, a další
Vydáno: (2013-01-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Autor: Ebers, G, a další
Vydáno: (1998)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
Autor: Filippini, G, a další
Vydáno: (2003)

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection
Autor: Xuan Feng, a další
Vydáno: (2019-11-01)

The evolution of interferon therapy in multiple sclerosis
Autor: O. V. Boyko, a další
Vydáno: (2023-08-01)

Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
Autor: V. Byrnes, a další
Vydáno: (2006-01-01)

Curcumin as an add-on therapy for multiple sclerosis in patients receiving interferon-beta therapy
Autor: A. D. Kukushkina, a další
Vydáno: (2024-08-01)

Association of smoking with risk of multiple sclerosis: a population-based study.
Autor: Ramagopalan, S, a další
Vydáno: (2013)

Association of smoking with risk of multiple sclerosis: A population-based study
Autor: Ramagopalan, S, a další
Vydáno: (2013)

Adherence to interferon β treatment in Kosovan multiple sclerosis registry
Autor: Blerim Myftiu, a další
Vydáno: (2024-01-01)

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
Autor: L. M. Kuzenkova, a další
Vydáno: (2013-09-01)

Interferon beta treatment of multiple sclerosis.
Autor: Markovitz, D
Vydáno: (1994)

CLINICALLY ISOLATED SYNDROME IN CHILDREN AND ADOLESCENTS — RISK FACTORS FOR MULTIPLE SCLEROSIS AND PROSPECTS OF USING INTRAMUSCULAR INTERFERON β-1A
Autor: O.V. Bykova, a další
Vydáno: (2010-05-01)